[1] Guyatt, G.H., Akl, E.A., Crowther, M., Gutterman, D.D. and Schuunemann, H.J. (2012) Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, 7S-47S.
[2] Wiesner, C. (2001) Arzneimittelsicherheit in der Perihospitalphase—Eine patientenbezogene Analyse des Pharmakotherapieprozesses. Ph.D. Thesis, University of Basel, Basel.
[3] Hepler, C.D. and Strand, L.M. (1990) Opportunities and Responsibilities in Pharmaceutical Care. American Journal of Hospital Pharmacy, 47, 533-543.
[4] Frokjaer, B., Sondergaard, B. and Herborg, H. (2004) Evidence Report 3—Follow-Up on Outcomes of Drug Therapy (Pharmaceutical Care). Pharmakon, 1-16.
[5] Blenkinsopp, A. and Hassey, A. (2005) Effectiveness and Acceptability of Community Pharmacy-Based Interventions in Type 2 Diabetes: A Critical Review of Intervention Design, Pharmacist and Patient Perspectives. International Journal of Pharmacy Practice, 13, 231-240. http://dx.doi.org/10.1211/ijpp.13.4.0001
[6] Roughead, E.E., Semple, S.J. and Vitry, A.I. (2005) Pharmaceutical Care Services: A Systematic Review of Published Studies, 1990 to 2003, Examining Effectiveness in Improving Patient Outcomes. International Journal of Pharmacy Practice, 13, 53-70. http://dx.doi.org/10.1211/0022357055551
[7] Machado, M., Bajcar, J., Guzzo, G.C. and Einarson, T.R. (2007) Sensitivity of Patient Outcomes to Pharmacist Interventions. Part II: Systematic Review and Meta-Analysis in Hypertension Management. The Annals of Pharmacotherapy, 41, 1770-1781. http://dx.doi.org/10.1345/aph.1K311
[8] Machado, M., Bajcar, J., Guzzo, G.C. and Einarson, T.R. (2007) Sensitivity of Patient Outcomes to Pharmacist Interventions. Part I: Systematic Review and Meta-Analysis in Diabetes Management. The Annals of Pharmacotherapy, 41, 1569-1582. http://dx.doi.org/10.1345/aph.1K151
[9] Machado, M., Nassor, N., Bajcar, J.M., Guzzo, G.C. and Einarson, T.R. (2008) Sensitivity of Patient Outcomes to Pharmacist Interventions. Part III: Systematic Review and Meta-Analysis in Hyperlipidemia Management. The Annals of Pharmacotherapy, 42, 1195-1207. http://dx.doi.org/10.1345/aph.1K618
[10] Wubben, D.P. and Vivian, E.M. (2008) Effects of Pharmacist Outpatient Interventions on Adults with Diabetes Mellitus: A Systematic Review. Pharmacotherapy, 28, 421-436. http://dx.doi.org/10.1592/phco.28.4.421
[11] Miller, N.H., Hill, M., Kottke, T. and Ockene, I.S. (1997) The Multilevel Compliance Challenge: Recommendations for a Call to Action. A Statement for Healthcare Professionals. Circulation, 95, 1085-1090.
http://dx.doi.org/10.1161/01.CIR.95.4.1085
[12] Haynes, R.B., Ackloo, E., Sahota, N., McDonald, H.P. and Yao, X. (2008) Interventions for Enhancing Medication Adherence. Cochrane Database of Systematic Reviews, 2, CD000011.
[13] Mengiardi, S., Goepfert, B., Tsakiris, D.A. and Hersberger, K.E. (2009) Pitfalls in Patient Self-Management of Subcutaneous Drug Application: Removal of Rubber Protection Caps from Ready-to-Use Syringes. European Journal of Clinical Pharmacology, 65, 1061-1062. http://dx.doi.org/10.1007/s00228-009-0681-0
[14] Mengiardi, S., Tsakiris, D.A., Lampert, M.L. and Hersberger, K.E. (2011) Drug Use Problems with Self-Injected Low-Molecular-Weight Heparins in Primary Care. European Journal of Clinical Pharmacology, 67, 109-120.
http://dx.doi.org/10.1007/s00228-010-0956-5
[15] Karch, A.M. (2004) A Needling Problem. American Journal of Nursing, 104, 81-83.
http://dx.doi.org/10.1097/00000446-200404000-00026
[16] Colwell, C.W., Pullido, P., Hardwick, M.E. and Morris, B.A. (2005) Patient Compliance with Outpatient Prophylaxis: An Observational Study. Orthopedics, 28, 143-147.
[17] Spahn, G. (2002) Compliance with Self-Administration of Heparin Injections in Outpatients. European Journal of Trauma and Emergency Surgery, 28, 104-109. http://dx.doi.org/10.1007/s00068-002-1176-1
[18] Watts, A.C., Howie, C.R. and Simpson, A.H. (2006) Assessment of a Self-Administration Protocol for Extended Subcutaneous Thromboprophylaxis in Lower Limb Arthroplasty. The Journal of Bone and Joint Surgery (British Volume), 88, 107-110. http://dx.doi.org/10.1302/0301-620X.88B1.17003
[19] Le Gall, C., Jacques, E., Medjebeur, C., Darques, L., Briand, F., Haddad, J., et al. (2006) Low Molecular Weight Heparin Self-Injection Training: Assessment of Feasibility, Tolerance and Economic Analysis in Emergency Departments. European Journal of Emergency Medicine, 13, 264-269. http://dx.doi.org/10.1097/00063110-200610000-00004
[20] Piazza, G., Nguyen, T.N., Morrison, R., Cios, D., Hohlfelder, B., Fanikos, J., et al. (2012) Patient Education Program for Venous Thromboembolism Prevention in Hospitalized Patients. The American Journal of Medicine, 125, 258-264.
http://dx.doi.org/10.1016/j.amjmed.2011.09.012
[21] Urbaniak, G.C. and Plous, S. (2007) Research Randomizer (Version 3.0). Computer Software.
http://www.randomizer.org/
[22] Zaybak, A. and Khorshid, L. (2008) A Study on the Effect of the Duration of Subcutaneous Heparin Injection on Bruising and Pain. Journal of Clinical Nursing, 17, 378-385.
[23] Chan, H. (2001) Effects of Injection Duration on Site-Pain Intensity and Bruising Associated with Subcutaneous Heparin. Journal of Advanced Nursing, 35, 882-892. http://dx.doi.org/10.1046/j.1365-2648.2001.01925.x
[24] Balci Akpinar, R. and Celebioglu, A. (2008) Effect of Injection Duration on Bruising Associated with Subcutaneous Heparin: A Quasi-Experimental within-Subject Design. International Journal of Nursing Studies, 45, 812-817.
http://dx.doi.org/10.1016/j.ijnurstu.2007.02.005
[25] Palese, A., Aidone, E., Dante, A. and Pea, F. (2013) Occurrence and Extent of Bruising According to Duration of Administration of Subcutaneous Low-Molecular-Weight Heparin: A Quasi-Experimental Case-Crossover Study. Journal of Cardiovascular Nursing, 28, 473-482. http://dx.doi.org/10.1097/JCN.0b013e3182578b87
[26] Harrison, L., McGinnis, J., Crowther, M., Ginsberg, J. and Hirsh, J. (1998) Assessment of Outpatient Treatment of Deep-Vein Thrombosis with Low-Molecular-Weight Heparin. Archives of Internal Medicine, 158, 2001-2003.
http://dx.doi.org/10.1001/archinte.158.18.2001
[27] Deakin, D.E., Mishreki, A., Aslam, N. and Docker, C. (2010) Patient Compliance with Extended Low Molecular Weight Heparin Injections Following Hip and Knee Arthroplasty. Hip International, 20, 555-558.
[28] Rubenacker, S., Kaiser, J. and Guschmann, M. (2013) Compliance of Patients Undergoing Thromboprophylaxis with Enoxaparin: The Comfort Study. Der Chirurg, 84, 235-242.
[29] Karlinski, M., Stolarczyk, A., Siuda, M. and Ziolkowski, M. (2006) Compliance with Low Molecular Weight Heparin in Ambulatory Orthopedic Patients. Ortopedia Traumatologia Rehabilitacja, 8, 633-638.
[30] Bergqvist, D., Arcelus, J.I. and Felicissimo, P. (2012) Post-Discharge Compliance to Venous Thromboembolism Prophylaxis in High-Risk Orthopaedic Surgery: Results from the Ethos Registry. Thrombosis and Haemostasis, 107, 280-287. http://dx.doi.org/10.1160/TH11-07-0464
[31] Wilke, T., Moock, J., Muller, S., Pfannkuche, M. and Kurth, A. (2010) Nonadherence in Outpatient Thrombosis Prophylaxis with Low Molecular Weight Heparins after Major Orthopaedic Surgery. Clinical Orthopaedics and Related Research, 468, 2437-2453. http://dx.doi.org/10.1007/s11999-010-1306-8
[32] Sackett, D.L. and Snow, J.C. (1979) The Magnitude of Compliance and Non Compliance. In: Haynes, R.B., Taylor, D.W. and Sackett, D.L., Eds., Compliance in Health Care, Johns Hopkins University Press, Baltimore, 11-22.
[33] Horne, R. and Weinman, J. (1999) Patients’ Beliefs about Prescribed Medicines and Their Role in Adherence to Treatment in Chronic Physical Illness. Journal of Psychosomatic Research, 47, 555-567.
http://dx.doi.org/10.1016/S0022-3999(99)00057-4
[34] Lebel, B., Malherbe, M., Gouzy, S., Parienti, J.J., Dutheil, J.J., Barrellier, M.T., et al. (2012) Oral Thromboprophylaxis Following Total Hip Replacement: The Issue of Compliance. Orthopaedics and Traumatology: Surgery and Research, 98, 186-192.
[35] Quante, M., Thate-Waschke, I. and Schofer, M. (2012) What Are the Reasons for Patient Preference? A Comparison between Oral and Subcutaneous Administration. Zeitschrift für Orthopädie und Unfallchirurgie, 150, 397-403.
[36] Wilke, T. (2009) Patient Preferences for an Oral Anticoagulant after Major Orthopedic Surgery: Results of a German Survey. Patient, 2, 39-49. http://dx.doi.org/10.2165/01312067-200902010-00005
[37] Weitz, J.I., Eikelboom, J.W. and Samama, M.M. (2012) New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e120S-e151S.
[38] Treasure, T. (2011) Venous Thromboembolism—Reducing the Risk. NICE Guideline.
http://www.nice.org.uk/guidance/cg92
[39] Turner, A.P., Williams, R.M., Sloan, A.P. and Haselkorn, J.K. (2009) Injection Anxiety Remains a Long-Term Barrier to Medication Adherence in Multiple Sclerosis. Rehabilitation Psychology, 54, 116-121.
http://dx.doi.org/10.1037/a0014460